Announcements Trials
Browse Landscape

Phase

Phase 4 5Phase 2 3Phase 1/2 3Phase 1 2Phase NA 1Phase EARLY_PHASE1 1Phase 2/3 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1Genitourinary 1CNS 1

Conditions

Renal Insufficiency 1Lymphoma, Follicular 1Kidney Failure, Chronic 1Glioma 1Glioblastoma 1

Interventions

Cyclophosphamide 626pembrolizumab 505Paclitaxel 456Gemcitabine 439Carboplatin 437Cisplatin 420Radiotherapy 382fludarabine 367Nivolumab 340Docetaxel 278Bevacizumab 276Irinotecan 258Magnetic Resonance Spectroscopy 245Fluorouracil 229Dexamethasone 225Specimen Handling 223Capecitabine 218Rituximab 206Oxaliplatin 201Cytarabine 201Ipilimumab 198Temozolomide 197Biopsy 197fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 174Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Sitagliptin Phosphate × Clear all
NCT07541781 2026-04-21

Sitagliptin in Recurrent/Progressive Grade 4 Glioma

University of Iowa

Phase 1 Not yet recruiting
45 enrolled
CNS

Glioblastoma, Glioma

NCT00418366 2015-08-19

A Study on the Effect of Kidney Disease on a Diabetes Medication (0431-008)

Merck Sharp & Dohme LLC

Phase 1 Completed
24 enrolled
GenitourinaryLymphoid

Kidney Failure, Chronic, Lymphoma, Follicular, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡